August 2018 in “bioRxiv (Cold Spring Harbor Laboratory)” This study identifies diltiazem as a promising repurposed drug for treating influenza, supported by its antiviral activity and gene modulation effects, leading to a Phase II clinical trial authorization.
100 citations
,
November 2021 in “Cell Research” This study found that SARS-CoV-2 hijacks the host factor IGF2BP1 to stabilize its RNA and enhance translation, and identified Cepharanthine and Trifluoperazine as potential treatments against the virus.
16 citations
,
December 2021 in “Frontiers in Endocrinology” This review discusses the role of sex hormones in COVID-19 severity and reports no new clinical results; the authors suggest further research for gender-based personalized treatment options.
52 citations
,
September 2022 in “Viruses” This review discusses the functions of SARS-CoV-2 non-structural proteins in facilitating immune evasion and highlights possible therapeutic strategies, reporting no new clinical results.
42 citations
,
January 2019 in “Frontiers in Immunology” This study identified diltiazem, a calcium channel blocker for hypertension, as a promising repurposed treatment for influenza, enhancing antiviral efficacy when combined with oseltamivir.
